Navigation Links
The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
Date:1/22/2009

WHITE PLAINS, N.Y. and PRINCETON, N.J., Jan. 22 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc. today announced a partnership to support Phase 2 development of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML).

Through the partnership, LLS will provide $3.7 million to support Celator's Phase 2B multicenter, randomized, open-label trial of CPX-351 versus intensive salvage therapy in adult patients less than or equal to 60 years of age with AML in first relapse. Celator expects to start patient enrollment in this study in the first quarter of 2009 in the United States and Canada.

The partnership between Celator and LLS is part of LLS's Therapy Acceleration Program (TAP), which supports private sector and academic-based projects with the goal of advancing investigational therapies with high prospects for providing near-term benefit to patients with blood cancers.

"Celator has discovered a novel way to deliver and enhance the activity of agents that have been the standard of care in AML for decades," said Louis DeGennaro, Ph.D., LLS's chief scientific officer. "There have been many attempts to improve outcomes in this patient population with little success. The data collected on CPX-351 to date, and the enthusiasm of clinical investigators involved in that research, suggest that Celator's approach holds real promise to advance the treatment of AML."

"We are very pleased that The Leukemia & Lymphoma Society sees the potential of CPX-351 and is making this substantial investment," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "LLS has created a well defined, streamlined process for accessing capital for promising new blood cancer treatments. This commitment enhances our ability to further the clinical development of CPX-351
'/>"/>

SOURCE Celator Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. September is Leukemia, Lymphoma and Myeloma Awareness Month
5. The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. Leukemia Drug Proves Safe and Effective Over the Long Term
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
11. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014   Zacks Equity Research highlights Epizyme ... the Day and Panera (Nasdaq: PNRA - Free Report ) ... provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ... (Nasdaq: SHPG - Free Report ). Here is ... of the Day : The biotech bull market ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... a focus on the Chinese situation. The report ... classifications, applications and industry chain structure. The particulate respirators ...
(Date:8/22/2014)... , Cali ., Aug. 22, 2014 ... Papillomavirus Conference shows that a therapy being developed by Hera ... two that cause 70 percent of all cervical cancer. ... blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according ... Broker , Ph.D., who presented the findings at the ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Global and Chinese Particulate Respirators Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... DIEGO, Jan. 31, 2011 Volcano Corporation (Nasdaq: ... of Massachusetts has issued a decision that ruled in ... Inc., and against LightLab Imaging, Inc., on all of ... 11-page decision also rejected LightLab,s request for injunctive relief. ...
... its continuing partnerships with Brazilian public health authorities and ... Mr. Nelson dos Santos as interim vice president of ... nonprofit organization whose mission is to improve the health ... programs that help ensure the quality, safety and benefit ...
Cached Medicine Technology:Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case 2New Interim Leadership for USP-Brazil 2
(Date:8/22/2014)... 265,000 Danes are acutely admitted to medical departments with ... and Aarhus University Hospital now shows that many of ... are sent home again without receiving a diagnosis of ... "Naturally, there is no need for a diagnosis if ... a serious illness. So some patients will always be ...
(Date:8/22/2014)... nurses at New York University,s Langone Medical Center (NYULMC) ... the youngest and most vulnerable down flights of stairs ... generated by Hurricane Sandy. , Now, a recent ... of Nursing (NYUCN) and of Dentistry (NYUCD), published in ... impact on NYULMC nurses, post-Sandy deployment to help address ...
(Date:8/22/2014)... August 22, 2014 Human induced pluripotent ... of regenerative medicine because they can be coaxed to ... always act as anticipated. They sometimes mutate, develop into ... a new study recently published in STEM CELLS Translational ... this, simply by removing the material used to reprogram ...
(Date:8/22/2014)... low levels of nicotine may reduce addiction without ... new study from the University of Waterloo. ... Cancer Epidemiology monitored the smoking behaviours of ... of cigarettes with markedly reduced nicotine levels. , ... of which have very similar levels of nicotine ...
(Date:8/22/2014)... 2014 Lincolnshire Marriott Resort is inviting ... a tap, announcing Marriott’s new iPad Mini promotion for ... this exclusive offer will receive a complimentary iPad Mini ... the day’s agenda with ease. Marriott’s Meeting Services app, ... and connect with their group with just a few ...
Breaking Medicine News(10 mins):Health News:Many patients are discharged without a diagnosis 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 3Health News:Removing Programming Material After Inducing Stem Cells Could Improve Their Regeneration Ability 2Health News:Smokers consume same amount of cigarettes regardless of nicotine levels 2Health News:Lincolnshire Marriott Resort Offers iPad Mini for Chicago Meeting Planners 2
... Oct. 5 "The good news is,that there ... Terry D. Hashey,Medical Director of First Coast Family ... Corral Flu Campaign. "The bad news,is that despite ... still,ranked below the national average of 69.3% for ...
... dietary supplement ... LipidShield Plus(TM), MELBOURNE, Fla., Oct. ... has expanded again and LipidShield Plus(TM) is,now available at Stop & ... breakthrough cholesterol,fighting product that has been clinically proven to lower cholesterol ...
... Oct. 5 /Xinhua-PRNewswire/ -- In a star-studded ... Olympics honored twelve,extraordinary individuals and the city ... made and continue to make to promote ... of people with intellectual,disabilities, and the Special ...
... SOUTH SAN FRANCISCO, Calif., Oct. 4 Sunesis,Pharmaceuticals, Inc. ... inducement stock options awards in accordance with NASDAQ,Marketplace Rule ... stock options cover an aggregate of 48,000 shares of,common ... an,exercise price equal to the fair market value of ...
... Calif., Oct. 4 The Integrated Healthcare,Association ... to physician,groups in California at its annual ... 47 most outstanding physician groups were,honored for ... care,quality measures, including preventive care and chronic ...
... HealthShares(TM) Inc., an investment,company with a series ... been informed by Standard & Poor,s, the calculating ... at the opening of,trading on October 8, 2007, ... (NasdaqGS: FOXH) in the,HealthShares(TM) Cardio Devices Index. ...
Cached Medicine News:Health News:Florida Health Care Community Stepping Up for the 2007-2008 Flu Season 2Health News:New Health Corp. Announces the Addition of Stop & Shop and Giant Supermarkets to its Retail Outlets 2Health News:Special Olympics 'Special Spirit in China Award Of Excellence' Presented to Dedicated Friends of Special Olympics and City of Shanghai 2Health News:Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 2Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 3Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 4Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Cardio Devices Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Cardio Devices Index 3
... Novagen's Vacuum Manifold system for sample ... to which a vacuum is applied, a ... accessories for convenience in sample handling. The ... elution of up to 12 samples simultaneously. ...
For regulating sample flow rate when using the QIAvac 24 Plus;...
For processing mini spin columns on QIAvac 6S;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
Medicine Products: